The Technology Development Board (TDB), Department of Science and Technology (DST) has extended support to Bioneemtec India, Chennai for the project titled “Manufacturing of Minoxidil, Tranexamic Acid, Dequalinium Chloride, their Intermediates and Drug Liposomes.”

The project seeks to commercialise indigenous green chemistry technologies for the production of critical pharmaceutical ingredients and advanced drug delivery systems, contributing to import substitution, sustainable manufacturing, and healthcare security.

The project focuses on establishing advanced manufacturing capabilities for pharmaceutical intermediates, Active Pharmaceutical Ingredients (APIs), and novel drug delivery systems through a combination of batch and continuous-flow chemistry technologies. By adopting modern process technologies, the initiative aims to improve production efficiency, product quality, operational safety, and environmental sustainability while reducing dependence on imported pharmaceutical intermediates.

A key component of the project is the commercialisation of an indigenous process for manufacturing tranexamic acid, an important therapeutic molecule used in the management of bleeding disorders. Developed using a cost-effective and environmentally responsible synthesis route, the technology is designed to deliver high-purity products while minimising waste generation and process complexity. The project will also support the domestic production of Minoxidil and Dequalinium Chloride along with their key intermediates, strengthening local manufacturing capabilities in pharmaceutical value chains that currently depend substantially on imports.

Adding an innovation dimension, Bioneemtec has developed proprietary Drug Liposome APIs based on advanced nanotechnology platforms. These liposomal formulations are being developed for therapeutic applications including breast and skin cancer management and have demonstrated promising results with controlled nanoparticle characteristics. The company has also initiated Intellectual Property (IP) protection for the technology, creating a foundation for future development of advanced targeted drug delivery solutions.

Speaking on the occasion, Rajesh Kumar Pathak, Secretary, TDB, stated, "The future of pharmaceutical manufacturing lies in sustainable, technology-driven production systems that combine quality, efficiency, and environmental responsibility. Indigenous development of advanced APIs, critical intermediates, and novel drug delivery platforms will be instrumental in strengthening India's position as a global pharmaceutical manufacturing hub. TDB is committed to supporting such innovative enterprises that are creating high-value technologies while contributing to import substitution and healthcare security."

Bioneemtec India stated that the project will enable the company to scale up commercialisation of its green chemistry-based manufacturing technologies and advanced pharmaceutical products. The support will accelerate the development of indigenous capabilities in API manufacturing and next-generation therapeutic formulations while creating opportunities for domestic and international markets.